Facilitated By

San Antonio Medical Foundation

A DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF EFLORNITHINE AND SULINDAC TO PREVENT RECURRENCE OF HIGH RISK ADENOMAS AND SECOND PRIMARY COLORECTAL CANCERS IN PATIENTS WITH STAGE 0-III COLON CANCER, PHASE III - PACES

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Karnad,Anand B
Funded by
UT HLTH SCI CENTER AT HOUSTON
Research Start Date
Status
Inactive
Clinical Care
Cancer